SlideShare a Scribd company logo
1 of 36
Download to read offline

03/22/15 1
Investigational New Drug
Application (INDA)
www.PharmInfopedia.com

 INTRODUCTION
 REGULATORY ASPECT
 TYPE OF IND
 REQUIERMENT IND
 CONTENT OF IND
 IND AMENDMENT
 ANNUAL REPORT OF IND
 CONCLUSION
03/22/15 2
WHAT I WILL TELL
www.PharmInfopedia.com

What is INDA
03/22/15 3
General introductionGeneral introduction
this data and information is generated andthis data and information is generated and
gathered from three broad areas:gathered from three broad areas:
Animal P’cology & Toxicology studiesAnimal P’cology & Toxicology studies
Manufacturing informationManufacturing information
Clinical Protocols & InvestigatorClinical Protocols & Investigator
InformationInformation
www.PharmInfopedia.com

 The regulations in 21 CFR 312 cover procedures
and requirements for Investigational New Drug
Applications (INDs)
 These regulations define the roles and
responsibilities of FDA reviewers, IND sponsors,
and clinical investigators
03/22/15 4
Regulation
www.PharmInfopedia.com

Sponsor
 A sponsor is an individual, company, institution, or
organization that takes responsibility for and
initiates a clinical study (21 CFR 312.3(b), 312.50)
03/22/15 5
Definitions
www.PharmInfopedia.com

A sponsor is responsible for:
 Selecting qualified investigators
 Ensuring study monitoring
 Maintaining an effective IND, and
 Ensuring AE risk information is provided to the FDA
and investigators
03/22/15 6
Sponsor
www.PharmInfopedia.com

Investigator
 An investigator is an individual under whose
immediate direction the study drug is
administered or dispensed. If a team is
involved, the leader is the investigator; other
team members are sub-investigators
(21 CFR 312(b), 312.60)
03/22/15 7
Definitions
www.PharmInfopedia.com

Sponsor-Investigator
 A sponsor-investigator is an individual
who both initiates and conducts a study
and under whose immediate direction the
study drug is administered or dispensed.
This person must follow the requirements
pertaining to a sponsor and those
pertaining to an investigator
(21 CFR 312(b))
03/22/15 9
Definitions
www.PharmInfopedia.com

03/22/15 10
IND Requirements
www.PharmInfopedia.com

1. Commercial IND
2. Emergency use IND
3. Treatment IND
03/22/15 13
TYPE OF IND
www.PharmInfopedia.com
 To focus FDA’s attention during early phase
of clinical research on assuring the safety of
human test subjects.
 To provide sponsors with a greater measure
of flexibility in conducting Phase 1 trials.
 To facilitate consultation between FDA &
sponsors, especially after there is an
indication that the new drug is safe and
efficacious in humans.
03/22/15 14
Objective
www.PharmInfopedia.com
 Cover Sheet (Form FDA 1571)
 Table of Contents
 Introductory Statement & General investigational
plan
 Investigator’s Brochure
 Protocols
 Chemistry, Manufacturing & Control Information
 Previous Human Experience with the Investigational
Drug
 Additional Information
03/22/15 15
IND Content Requirements
21 CFR 312.23
www.PharmInfopedia.com

 The form is provided for basic information
like name of drug, submission date, sponsor
identification, phase of proposed clinical
investigation, sponsor commitments,
identification of clinical monitor and safety
evaluator, information regarding transfer of
responsibilities to a contract research
organization.
03/22/15 16
Cover Sheet (form FDA
1571)
www.PharmInfopedia.com

Drug Name®
IND table of contents
Item title volume/page
Introductory statement &
general investigational plan…
(i) Introductory statement….
(ii) summary of previous human experience
with drug…….
(iii) If the drug has been withdrawn from
Investigation/Marketing……
03/22/15 17
Table of Contents
www.PharmInfopedia.com

03/22/15 18
iv)iv) General Investigational Plan…..General Investigational Plan…..
5 Investigator’s Brochure…….5 Investigator’s Brochure…….
6 Protocol……..6 Protocol……..
7 Chemistry, Manufacturing & Control7 Chemistry, Manufacturing & Control
Information…Information…
(a) Drug substance…………(a) Drug substance…………
(b) Drug Product…………….(b) Drug Product…………….
(c) Placebo (if applicable)…(c) Placebo (if applicable)…
(d) Labeling…………………….(d) Labeling…………………….
(e) Environmental Analysis ….(e) Environmental Analysis ….
8 Pharmacology & Toxicology8 Pharmacology & Toxicology
Information…….Information…….
www.PharmInfopedia.com

9)Previous Human Experience with the
Investigational Drug…….
(i) Summary of Previous Human Experience….
(ii) If the drug is a combination of drug
previously investigated/marketed…….
(iii) If the drug has been marketed outside the
United States……
10 Additional Information (as applicable for
radioactive drugs or drugs with dependence or
abuse potential)….
03/22/15 19www.PharmInfopedia.com

It consists of four subsections:
1st
subsection: (introductory statement)
 Name of drug
 P’cological Class
 Structural formula
 Route of administration
 Broad objectives
 Planned duration of the proposed clinical
investigation03/22/15 20
Introductory Statement & General
Investigational Plan:
www.PharmInfopedia.com

2nd
subsection:
 Brief summary of any previous human
experience with the drug, including
investigational or marketing experience in other
countries
3rd
subsection:
 It is a statement as to whether or not the drug
has been withdrawn from investigation or
marketing in any country for any reason of
safety or efficacy
03/22/15 21www.PharmInfopedia.com

4th
subsection:
 Brief description of overall investigational plan for
drug during the following year like: Indications to be
studied, kinds of clinical trials to be conducted in
first year
03/22/15 22www.PharmInfopedia.com

 Sponsor must provide to all clinical
investigators, not required for sponsor
investigators (21 CFR 312.55). It must
include:
 Brief product description
 Pharm/tox summaries
 Previous human experience
 Description of anticipated risk and any special
monitoring needs
 Updates as appropriate03/22/15 23
Investigator’s Brochure (IB)
www.PharmInfopedia.com

Drug Name®
Investigator's Brochure
Table of contents
Page
Introduction……………………..
Chemistry……………………….
Physical Properties……
How Supplied…………….
Pharmacology………………….
Specific Effect Studies…
General Studies………….
03/22/15 24www.PharmInfopedia.com

Toxicology………………………..
Acute Toxicity…………….
Multidose Toxicity……….
Special Toxicity Studies………
Reproductive Studies……
Mutagenicity Studies…….
Pharmacokinetics………………
Preclinical…………………….
Clinical………………………….
Clinical Trial……………………….
Phase 1…………………………
Phase 2/3… ………………….
03/22/15 25www.PharmInfopedia.com

Safety/Efficacy Overview
Safety…………………………..
Efficacy………………………..
Possible Risks and Side Effects…
References………………………….
03/22/15 26www.PharmInfopedia.com

 Phase 1 protocol provides an outline of
investigation by specifying information
such as estimated number of test
subjects, inclusion/exclusion criteria and
dosing plan
 Phase 2 and Phase 3 protocols are detailed,
describing all aspects of the studies, such
that any deviation in a design if required, it
can be established in the protocol from
the beginning.
03/22/15 28
5 Protocols
www.PharmInfopedia.com

All the protocols are required to contain the
following elements:
 Statement of the objectives and purpose of the study
 Patient inclusion/exclusion criteria
 Estimate of number of patients to be studied
 Description of study design
 Dosing information including planned maximum
dosage and duration of individual patient exposure to
the Drug
 Description of the observations and measurements
planned to fulfill the study objectives
03/22/15 29www.PharmInfopedia.com

 Emphasis in Phase I is on identification and
control of raw materials and new drug substance,
including information on any placebo as well
 Even for Phase I, need enough information to
assess safety
 Extent of expected information increases as drug
development proceeds
 Throughout product development, good
documentation of all manufacturing and testing
steps is essential
 Deficiencies in CMC information can result in
clinical hold03/22/15 30
CMC Information
www.PharmInfopedia.com

 Previous human experience needs to be included (if
applicable)
 Additional information such as pre-IND meeting
minutes or critical references should be included as
well
 Serial numbering of pages of an IND is required (21
CFR 312.23(11)(e)) as this facilitates reference if the
FDA has questions
03/22/15 32
Other IND Items
www.PharmInfopedia.com

21 CFR 312.30
 A new protocol
 Safety or design related changes to an
existing protocol
 New investigator (notification is required
within 30 days of being added)
 These should be submitted to the FDA prior
to implementation
 IRB approval is needed prior to
implementation03/22/15 33
IND Protocol
Amendments
www.PharmInfopedia.com

21 CFR 312.31
Information amendments advise the FDA of:
 New tox, CMC or other technical information
 Notice of discontinuance of a clinical study
03/22/15 34
IND Information
Amendments
www.PharmInfopedia.com

 If a sponsor notify any unexpected fatal / life
threatening experience associated with the use of the
drug requires to notify the FDA by telephone no
later than 3 working days after receipt of the
information, followed by a written report within 10
days.
03/22/15 35
IND Safety Reports:
www.PharmInfopedia.com

21 CFR 312.33
 To be submitted within 60 days of the
anniversary of “in effect” date
 Include enrollment, demographic and
conduct status information for each study
 Adverse event summaries (safety reports,
deaths, dropouts)
 Drug action information
 Preclinical study status information03/22/15 36
Annual Reports
www.PharmInfopedia.com

 CMC change information
 Revised/updated investigator brochure with
revisions described
 Foreign marketing experience
 Outstanding business with the FDA
03/22/15 37
Annual Reports (cont’d)
www.PharmInfopedia.com

It is option of a sponsor to withdraw an IND at any
time without prejudice.
On withdrawn, sponsor must notify the FDA.
03/22/15 43
Withdrawal of an IND
www.PharmInfopedia.com

Two major outcomes from the IND discussion
are:
 30 days after an IND is submitted to the FDA, if the
sponsor has not heard anything from the FDA it
can be assumed that the drug is not on a clinical
hold and clinical trials may be started
 The Investigator’s Brochure, which will be used
during that important first clinical study and in
every clinical study thereafter, acts as the approved
labeling for the drug while it is under an IND
03/22/15 44
Conclusions
www.PharmInfopedia.com

1.www.fda.gov/cder/about/history/time1.htm
2.Remington the science and practice of pharmacy,
20th edition, Lippincott,Williams & Wilkins, page
no: 930-943
3. New Drug Approval Process: second Edition,
Revised and Expanded, edited by Richard A.
Guarino page no: 39-64, 243-263
4.www.fda.gov/cder/handbook/indbox.htm
5.www.fda.gov/cder/handbook/ndabox.htm
6.www.fda.gov
03/22/15 46
List of references
www.PharmInfopedia.com

03/22/15 47www.PharmInfopedia.com

More Related Content

What's hot

NEW DRUG APPLICATION (NDA)
NEW DRUG APPLICATION (NDA)NEW DRUG APPLICATION (NDA)
NEW DRUG APPLICATION (NDA)GOKULAKRISHNAN S
 
GCP for Investigators by Valentyna
GCP for Investigators by ValentynaGCP for Investigators by Valentyna
GCP for Investigators by ValentynaValentyna Korniyenko
 
new drug application
new drug applicationnew drug application
new drug applicationPRANJAY PATIL
 
Post marketing servillence
Post marketing servillencePost marketing servillence
Post marketing servillencebdvfgbdhg
 
INVESTIGATIONAL NEW DRUG APPLICATION
INVESTIGATIONAL NEW DRUG APPLICATIONINVESTIGATIONAL NEW DRUG APPLICATION
INVESTIGATIONAL NEW DRUG APPLICATIONBindu Kshtriya
 
Investigator's brochure
Investigator's brochureInvestigator's brochure
Investigator's brochureAtul Adhikari
 
New drug application
New drug applicationNew drug application
New drug applicationVKEkbote
 
Regulatory Requirements for Drug Product Approval
Regulatory Requirements for Drug Product ApprovalRegulatory Requirements for Drug Product Approval
Regulatory Requirements for Drug Product ApprovalAtul Adhikari
 
THERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRA
THERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRATHERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRA
THERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRAManikant Prasad Shah
 
Non clinical drug development. ppt
Non clinical drug development. pptNon clinical drug development. ppt
Non clinical drug development. pptPRABU12345678
 
Pharmacovigilance safety Mon. in clinical trials.pptx
Pharmacovigilance safety Mon. in clinical trials.pptxPharmacovigilance safety Mon. in clinical trials.pptx
Pharmacovigilance safety Mon. in clinical trials.pptxRoshan Yadav
 
Regulatory Requirements For New Drug Approval
Regulatory Requirements For New Drug ApprovalRegulatory Requirements For New Drug Approval
Regulatory Requirements For New Drug ApprovalShagufta Farooqui
 
Ind (investigational new drug application) and nda
Ind (investigational new drug application) and ndaInd (investigational new drug application) and nda
Ind (investigational new drug application) and ndaswati2084
 
Investigational new drug application
Investigational new drug application Investigational new drug application
Investigational new drug application Kirsha K S
 
Code of federal regulations {cfr} in pharmaceutical
Code of federal regulations {cfr} in pharmaceuticalCode of federal regulations {cfr} in pharmaceutical
Code of federal regulations {cfr} in pharmaceuticalArabinda Changmai
 
Regulatory approval and system of drug master file ,IND and NDA in USA
Regulatory approval and system of  drug master file ,IND  and NDA in USARegulatory approval and system of  drug master file ,IND  and NDA in USA
Regulatory approval and system of drug master file ,IND and NDA in USAsandeep bansal
 
Therapeutic goods adminstration
Therapeutic goods adminstration   Therapeutic goods adminstration
Therapeutic goods adminstration Pranali Palandurkar
 

What's hot (20)

NEW DRUG APPLICATION (NDA)
NEW DRUG APPLICATION (NDA)NEW DRUG APPLICATION (NDA)
NEW DRUG APPLICATION (NDA)
 
GCP for Investigators by Valentyna
GCP for Investigators by ValentynaGCP for Investigators by Valentyna
GCP for Investigators by Valentyna
 
new drug application
new drug applicationnew drug application
new drug application
 
Post marketing servillence
Post marketing servillencePost marketing servillence
Post marketing servillence
 
INDA/NDA/ANDA
INDA/NDA/ANDAINDA/NDA/ANDA
INDA/NDA/ANDA
 
INVESTIGATIONAL NEW DRUG APPLICATION
INVESTIGATIONAL NEW DRUG APPLICATIONINVESTIGATIONAL NEW DRUG APPLICATION
INVESTIGATIONAL NEW DRUG APPLICATION
 
Investigator's brochure
Investigator's brochureInvestigator's brochure
Investigator's brochure
 
ind
indind
ind
 
New drug application
New drug applicationNew drug application
New drug application
 
Regulatory Requirements for Drug Product Approval
Regulatory Requirements for Drug Product ApprovalRegulatory Requirements for Drug Product Approval
Regulatory Requirements for Drug Product Approval
 
Schedule y
Schedule ySchedule y
Schedule y
 
THERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRA
THERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRATHERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRA
THERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRA
 
Non clinical drug development. ppt
Non clinical drug development. pptNon clinical drug development. ppt
Non clinical drug development. ppt
 
Pharmacovigilance safety Mon. in clinical trials.pptx
Pharmacovigilance safety Mon. in clinical trials.pptxPharmacovigilance safety Mon. in clinical trials.pptx
Pharmacovigilance safety Mon. in clinical trials.pptx
 
Regulatory Requirements For New Drug Approval
Regulatory Requirements For New Drug ApprovalRegulatory Requirements For New Drug Approval
Regulatory Requirements For New Drug Approval
 
Ind (investigational new drug application) and nda
Ind (investigational new drug application) and ndaInd (investigational new drug application) and nda
Ind (investigational new drug application) and nda
 
Investigational new drug application
Investigational new drug application Investigational new drug application
Investigational new drug application
 
Code of federal regulations {cfr} in pharmaceutical
Code of federal regulations {cfr} in pharmaceuticalCode of federal regulations {cfr} in pharmaceutical
Code of federal regulations {cfr} in pharmaceutical
 
Regulatory approval and system of drug master file ,IND and NDA in USA
Regulatory approval and system of  drug master file ,IND  and NDA in USARegulatory approval and system of  drug master file ,IND  and NDA in USA
Regulatory approval and system of drug master file ,IND and NDA in USA
 
Therapeutic goods adminstration
Therapeutic goods adminstration   Therapeutic goods adminstration
Therapeutic goods adminstration
 

Similar to Investigational new drug application

akshay regulatory seminar 1 productregistrationanddrugapprovalprocessinus.ppt
akshay regulatory seminar 1    productregistrationanddrugapprovalprocessinus.pptakshay regulatory seminar 1    productregistrationanddrugapprovalprocessinus.ppt
akshay regulatory seminar 1 productregistrationanddrugapprovalprocessinus.pptGaneshSureshKumbhar
 
Product registration and drug approval process in us
Product registration and drug approval process in usProduct registration and drug approval process in us
Product registration and drug approval process in uskeerthi09
 
IND (Investigational New Drug) industrial perspective
IND (Investigational New Drug) industrial perspectiveIND (Investigational New Drug) industrial perspective
IND (Investigational New Drug) industrial perspectiveAYESHA NAZEER
 
NEW DRUG APPLICATION
NEW DRUG APPLICATIONNEW DRUG APPLICATION
NEW DRUG APPLICATIONSACHIN C P
 
ABBREVIATED NEW DRUG APPLICATION (ANDA),INVESTICATION OF MEDICINAL PRODUCTS D...
ABBREVIATED NEW DRUG APPLICATION (ANDA),INVESTICATION OF MEDICINAL PRODUCTS D...ABBREVIATED NEW DRUG APPLICATION (ANDA),INVESTICATION OF MEDICINAL PRODUCTS D...
ABBREVIATED NEW DRUG APPLICATION (ANDA),INVESTICATION OF MEDICINAL PRODUCTS D...GOKULAKRISHNAN S
 
GLOBAL SUBMISSION OF IND, NDA, ANDA.pdf
GLOBAL SUBMISSION OF IND, NDA, ANDA.pdfGLOBAL SUBMISSION OF IND, NDA, ANDA.pdf
GLOBAL SUBMISSION OF IND, NDA, ANDA.pdfLokeshThakre6
 
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...Audumbar Mali
 
Content_of_an_Investigational_New_Drug_Application_(IND).pdf
Content_of_an_Investigational_New_Drug_Application_(IND).pdfContent_of_an_Investigational_New_Drug_Application_(IND).pdf
Content_of_an_Investigational_New_Drug_Application_(IND).pdfMadhukarSureshThagna
 
New drug application
New drug applicationNew drug application
New drug applicationnishuyadav17
 
Regulatory guidance and guidelines for filing and approval for biologics
Regulatory guidance and guidelines for filing and approval for biologicsRegulatory guidance and guidelines for filing and approval for biologics
Regulatory guidance and guidelines for filing and approval for biologicsNimmiRoy
 
2.IND AND ANDA.pptx
2.IND AND ANDA.pptx2.IND AND ANDA.pptx
2.IND AND ANDA.pptxbrahmaiahmph
 
Regulatory Affairs - IND,NDA,ANDA
Regulatory Affairs - IND,NDA,ANDARegulatory Affairs - IND,NDA,ANDA
Regulatory Affairs - IND,NDA,ANDALingrajGc
 

Similar to Investigational new drug application (20)

akshay regulatory seminar 1 productregistrationanddrugapprovalprocessinus.ppt
akshay regulatory seminar 1    productregistrationanddrugapprovalprocessinus.pptakshay regulatory seminar 1    productregistrationanddrugapprovalprocessinus.ppt
akshay regulatory seminar 1 productregistrationanddrugapprovalprocessinus.ppt
 
Product registration and drug approval process in us
Product registration and drug approval process in usProduct registration and drug approval process in us
Product registration and drug approval process in us
 
ANDA, IMPD & IB
ANDA, IMPD & IBANDA, IMPD & IB
ANDA, IMPD & IB
 
NDS V'S ANDA
NDS V'S ANDANDS V'S ANDA
NDS V'S ANDA
 
IND (Investigational New Drug) industrial perspective
IND (Investigational New Drug) industrial perspectiveIND (Investigational New Drug) industrial perspective
IND (Investigational New Drug) industrial perspective
 
6 ind
6 ind6 ind
6 ind
 
NEW DRUG APPLICATION
NEW DRUG APPLICATIONNEW DRUG APPLICATION
NEW DRUG APPLICATION
 
ABBREVIATED NEW DRUG APPLICATION (ANDA),INVESTICATION OF MEDICINAL PRODUCTS D...
ABBREVIATED NEW DRUG APPLICATION (ANDA),INVESTICATION OF MEDICINAL PRODUCTS D...ABBREVIATED NEW DRUG APPLICATION (ANDA),INVESTICATION OF MEDICINAL PRODUCTS D...
ABBREVIATED NEW DRUG APPLICATION (ANDA),INVESTICATION OF MEDICINAL PRODUCTS D...
 
GLOBAL SUBMISSION OF IND, NDA, ANDA.pdf
GLOBAL SUBMISSION OF IND, NDA, ANDA.pdfGLOBAL SUBMISSION OF IND, NDA, ANDA.pdf
GLOBAL SUBMISSION OF IND, NDA, ANDA.pdf
 
Ind by pankaj
Ind by pankajInd by pankaj
Ind by pankaj
 
Nda
NdaNda
Nda
 
NDA Vs ANDA
NDA Vs ANDANDA Vs ANDA
NDA Vs ANDA
 
10512fnl2-16-2016
10512fnl2-16-201610512fnl2-16-2016
10512fnl2-16-2016
 
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
 
2103313002_Harsh Gandhi_MP104T.pptx
2103313002_Harsh Gandhi_MP104T.pptx2103313002_Harsh Gandhi_MP104T.pptx
2103313002_Harsh Gandhi_MP104T.pptx
 
Content_of_an_Investigational_New_Drug_Application_(IND).pdf
Content_of_an_Investigational_New_Drug_Application_(IND).pdfContent_of_an_Investigational_New_Drug_Application_(IND).pdf
Content_of_an_Investigational_New_Drug_Application_(IND).pdf
 
New drug application
New drug applicationNew drug application
New drug application
 
Regulatory guidance and guidelines for filing and approval for biologics
Regulatory guidance and guidelines for filing and approval for biologicsRegulatory guidance and guidelines for filing and approval for biologics
Regulatory guidance and guidelines for filing and approval for biologics
 
2.IND AND ANDA.pptx
2.IND AND ANDA.pptx2.IND AND ANDA.pptx
2.IND AND ANDA.pptx
 
Regulatory Affairs - IND,NDA,ANDA
Regulatory Affairs - IND,NDA,ANDARegulatory Affairs - IND,NDA,ANDA
Regulatory Affairs - IND,NDA,ANDA
 

More from Gaurav Kr

Instrumental analysis
Instrumental analysisInstrumental analysis
Instrumental analysisGaurav Kr
 
Fractional factorial design tutorial
Fractional factorial design tutorialFractional factorial design tutorial
Fractional factorial design tutorialGaurav Kr
 
Herbal medicine
Herbal medicineHerbal medicine
Herbal medicineGaurav Kr
 
Investigational new drug application
Investigational new drug applicationInvestigational new drug application
Investigational new drug applicationGaurav Kr
 
Gmp for water for p'cal use
Gmp for water for p'cal useGmp for water for p'cal use
Gmp for water for p'cal useGaurav Kr
 
Gmp compliance
Gmp complianceGmp compliance
Gmp complianceGaurav Kr
 
GMP and cGMP
GMP and cGMPGMP and cGMP
GMP and cGMPGaurav Kr
 
Drug master files
Drug master filesDrug master files
Drug master filesGaurav Kr
 
Drug development and nda
Drug development and ndaDrug development and nda
Drug development and ndaGaurav Kr
 
Dosage form design
Dosage form designDosage form design
Dosage form designGaurav Kr
 
Control of microbial growth
Control of microbial growthControl of microbial growth
Control of microbial growthGaurav Kr
 
Computer system validation
Computer system validationComputer system validation
Computer system validationGaurav Kr
 
Designing around patent
Designing around patentDesigning around patent
Designing around patentGaurav Kr
 
Clinical trails
Clinical trailsClinical trails
Clinical trailsGaurav Kr
 
Clinical study and gcp
Clinical study and gcpClinical study and gcp
Clinical study and gcpGaurav Kr
 
Clinical research
Clinical researchClinical research
Clinical researchGaurav Kr
 

More from Gaurav Kr (20)

Instrumental analysis
Instrumental analysisInstrumental analysis
Instrumental analysis
 
Fractional factorial design tutorial
Fractional factorial design tutorialFractional factorial design tutorial
Fractional factorial design tutorial
 
Herbals
HerbalsHerbals
Herbals
 
Herbal medicine
Herbal medicineHerbal medicine
Herbal medicine
 
Investigational new drug application
Investigational new drug applicationInvestigational new drug application
Investigational new drug application
 
Gmp for water for p'cal use
Gmp for water for p'cal useGmp for water for p'cal use
Gmp for water for p'cal use
 
Gmp compliance
Gmp complianceGmp compliance
Gmp compliance
 
GMP and cGMP
GMP and cGMPGMP and cGMP
GMP and cGMP
 
Foi and iig
Foi and iigFoi and iig
Foi and iig
 
Drug master files
Drug master filesDrug master files
Drug master files
 
Drug development and nda
Drug development and ndaDrug development and nda
Drug development and nda
 
EMEA
EMEAEMEA
EMEA
 
Dosage form design
Dosage form designDosage form design
Dosage form design
 
Control of microbial growth
Control of microbial growthControl of microbial growth
Control of microbial growth
 
Computer system validation
Computer system validationComputer system validation
Computer system validation
 
Designing around patent
Designing around patentDesigning around patent
Designing around patent
 
Clinical trails
Clinical trailsClinical trails
Clinical trails
 
Clinical study and gcp
Clinical study and gcpClinical study and gcp
Clinical study and gcp
 
Clinical research
Clinical researchClinical research
Clinical research
 
Cder
CderCder
Cder
 

Investigational new drug application

  • 1.  03/22/15 1 Investigational New Drug Application (INDA) www.PharmInfopedia.com
  • 2.   INTRODUCTION  REGULATORY ASPECT  TYPE OF IND  REQUIERMENT IND  CONTENT OF IND  IND AMENDMENT  ANNUAL REPORT OF IND  CONCLUSION 03/22/15 2 WHAT I WILL TELL www.PharmInfopedia.com
  • 3.  What is INDA 03/22/15 3 General introductionGeneral introduction this data and information is generated andthis data and information is generated and gathered from three broad areas:gathered from three broad areas: Animal P’cology & Toxicology studiesAnimal P’cology & Toxicology studies Manufacturing informationManufacturing information Clinical Protocols & InvestigatorClinical Protocols & Investigator InformationInformation www.PharmInfopedia.com
  • 4.   The regulations in 21 CFR 312 cover procedures and requirements for Investigational New Drug Applications (INDs)  These regulations define the roles and responsibilities of FDA reviewers, IND sponsors, and clinical investigators 03/22/15 4 Regulation www.PharmInfopedia.com
  • 5.  Sponsor  A sponsor is an individual, company, institution, or organization that takes responsibility for and initiates a clinical study (21 CFR 312.3(b), 312.50) 03/22/15 5 Definitions www.PharmInfopedia.com
  • 6.  A sponsor is responsible for:  Selecting qualified investigators  Ensuring study monitoring  Maintaining an effective IND, and  Ensuring AE risk information is provided to the FDA and investigators 03/22/15 6 Sponsor www.PharmInfopedia.com
  • 7.  Investigator  An investigator is an individual under whose immediate direction the study drug is administered or dispensed. If a team is involved, the leader is the investigator; other team members are sub-investigators (21 CFR 312(b), 312.60) 03/22/15 7 Definitions www.PharmInfopedia.com
  • 8.  Sponsor-Investigator  A sponsor-investigator is an individual who both initiates and conducts a study and under whose immediate direction the study drug is administered or dispensed. This person must follow the requirements pertaining to a sponsor and those pertaining to an investigator (21 CFR 312(b)) 03/22/15 9 Definitions www.PharmInfopedia.com
  • 10.  1. Commercial IND 2. Emergency use IND 3. Treatment IND 03/22/15 13 TYPE OF IND www.PharmInfopedia.com
  • 11.  To focus FDA’s attention during early phase of clinical research on assuring the safety of human test subjects.  To provide sponsors with a greater measure of flexibility in conducting Phase 1 trials.  To facilitate consultation between FDA & sponsors, especially after there is an indication that the new drug is safe and efficacious in humans. 03/22/15 14 Objective www.PharmInfopedia.com
  • 12.  Cover Sheet (Form FDA 1571)  Table of Contents  Introductory Statement & General investigational plan  Investigator’s Brochure  Protocols  Chemistry, Manufacturing & Control Information  Previous Human Experience with the Investigational Drug  Additional Information 03/22/15 15 IND Content Requirements 21 CFR 312.23 www.PharmInfopedia.com
  • 13.   The form is provided for basic information like name of drug, submission date, sponsor identification, phase of proposed clinical investigation, sponsor commitments, identification of clinical monitor and safety evaluator, information regarding transfer of responsibilities to a contract research organization. 03/22/15 16 Cover Sheet (form FDA 1571) www.PharmInfopedia.com
  • 14.  Drug Name® IND table of contents Item title volume/page Introductory statement & general investigational plan… (i) Introductory statement…. (ii) summary of previous human experience with drug……. (iii) If the drug has been withdrawn from Investigation/Marketing…… 03/22/15 17 Table of Contents www.PharmInfopedia.com
  • 15.  03/22/15 18 iv)iv) General Investigational Plan…..General Investigational Plan….. 5 Investigator’s Brochure…….5 Investigator’s Brochure……. 6 Protocol……..6 Protocol…….. 7 Chemistry, Manufacturing & Control7 Chemistry, Manufacturing & Control Information…Information… (a) Drug substance…………(a) Drug substance………… (b) Drug Product…………….(b) Drug Product……………. (c) Placebo (if applicable)…(c) Placebo (if applicable)… (d) Labeling…………………….(d) Labeling……………………. (e) Environmental Analysis ….(e) Environmental Analysis …. 8 Pharmacology & Toxicology8 Pharmacology & Toxicology Information…….Information……. www.PharmInfopedia.com
  • 16.  9)Previous Human Experience with the Investigational Drug……. (i) Summary of Previous Human Experience…. (ii) If the drug is a combination of drug previously investigated/marketed……. (iii) If the drug has been marketed outside the United States…… 10 Additional Information (as applicable for radioactive drugs or drugs with dependence or abuse potential)…. 03/22/15 19www.PharmInfopedia.com
  • 17.  It consists of four subsections: 1st subsection: (introductory statement)  Name of drug  P’cological Class  Structural formula  Route of administration  Broad objectives  Planned duration of the proposed clinical investigation03/22/15 20 Introductory Statement & General Investigational Plan: www.PharmInfopedia.com
  • 18.  2nd subsection:  Brief summary of any previous human experience with the drug, including investigational or marketing experience in other countries 3rd subsection:  It is a statement as to whether or not the drug has been withdrawn from investigation or marketing in any country for any reason of safety or efficacy 03/22/15 21www.PharmInfopedia.com
  • 19.  4th subsection:  Brief description of overall investigational plan for drug during the following year like: Indications to be studied, kinds of clinical trials to be conducted in first year 03/22/15 22www.PharmInfopedia.com
  • 20.   Sponsor must provide to all clinical investigators, not required for sponsor investigators (21 CFR 312.55). It must include:  Brief product description  Pharm/tox summaries  Previous human experience  Description of anticipated risk and any special monitoring needs  Updates as appropriate03/22/15 23 Investigator’s Brochure (IB) www.PharmInfopedia.com
  • 21.  Drug Name® Investigator's Brochure Table of contents Page Introduction…………………….. Chemistry………………………. Physical Properties…… How Supplied……………. Pharmacology…………………. Specific Effect Studies… General Studies…………. 03/22/15 24www.PharmInfopedia.com
  • 22.  Toxicology……………………….. Acute Toxicity……………. Multidose Toxicity………. Special Toxicity Studies……… Reproductive Studies…… Mutagenicity Studies……. Pharmacokinetics……………… Preclinical……………………. Clinical…………………………. Clinical Trial………………………. Phase 1………………………… Phase 2/3… …………………. 03/22/15 25www.PharmInfopedia.com
  • 23.  Safety/Efficacy Overview Safety………………………….. Efficacy……………………….. Possible Risks and Side Effects… References…………………………. 03/22/15 26www.PharmInfopedia.com
  • 24.   Phase 1 protocol provides an outline of investigation by specifying information such as estimated number of test subjects, inclusion/exclusion criteria and dosing plan  Phase 2 and Phase 3 protocols are detailed, describing all aspects of the studies, such that any deviation in a design if required, it can be established in the protocol from the beginning. 03/22/15 28 5 Protocols www.PharmInfopedia.com
  • 25.  All the protocols are required to contain the following elements:  Statement of the objectives and purpose of the study  Patient inclusion/exclusion criteria  Estimate of number of patients to be studied  Description of study design  Dosing information including planned maximum dosage and duration of individual patient exposure to the Drug  Description of the observations and measurements planned to fulfill the study objectives 03/22/15 29www.PharmInfopedia.com
  • 26.   Emphasis in Phase I is on identification and control of raw materials and new drug substance, including information on any placebo as well  Even for Phase I, need enough information to assess safety  Extent of expected information increases as drug development proceeds  Throughout product development, good documentation of all manufacturing and testing steps is essential  Deficiencies in CMC information can result in clinical hold03/22/15 30 CMC Information www.PharmInfopedia.com
  • 27.   Previous human experience needs to be included (if applicable)  Additional information such as pre-IND meeting minutes or critical references should be included as well  Serial numbering of pages of an IND is required (21 CFR 312.23(11)(e)) as this facilitates reference if the FDA has questions 03/22/15 32 Other IND Items www.PharmInfopedia.com
  • 28.  21 CFR 312.30  A new protocol  Safety or design related changes to an existing protocol  New investigator (notification is required within 30 days of being added)  These should be submitted to the FDA prior to implementation  IRB approval is needed prior to implementation03/22/15 33 IND Protocol Amendments www.PharmInfopedia.com
  • 29.  21 CFR 312.31 Information amendments advise the FDA of:  New tox, CMC or other technical information  Notice of discontinuance of a clinical study 03/22/15 34 IND Information Amendments www.PharmInfopedia.com
  • 30.   If a sponsor notify any unexpected fatal / life threatening experience associated with the use of the drug requires to notify the FDA by telephone no later than 3 working days after receipt of the information, followed by a written report within 10 days. 03/22/15 35 IND Safety Reports: www.PharmInfopedia.com
  • 31.  21 CFR 312.33  To be submitted within 60 days of the anniversary of “in effect” date  Include enrollment, demographic and conduct status information for each study  Adverse event summaries (safety reports, deaths, dropouts)  Drug action information  Preclinical study status information03/22/15 36 Annual Reports www.PharmInfopedia.com
  • 32.   CMC change information  Revised/updated investigator brochure with revisions described  Foreign marketing experience  Outstanding business with the FDA 03/22/15 37 Annual Reports (cont’d) www.PharmInfopedia.com
  • 33.  It is option of a sponsor to withdraw an IND at any time without prejudice. On withdrawn, sponsor must notify the FDA. 03/22/15 43 Withdrawal of an IND www.PharmInfopedia.com
  • 34.  Two major outcomes from the IND discussion are:  30 days after an IND is submitted to the FDA, if the sponsor has not heard anything from the FDA it can be assumed that the drug is not on a clinical hold and clinical trials may be started  The Investigator’s Brochure, which will be used during that important first clinical study and in every clinical study thereafter, acts as the approved labeling for the drug while it is under an IND 03/22/15 44 Conclusions www.PharmInfopedia.com
  • 35.  1.www.fda.gov/cder/about/history/time1.htm 2.Remington the science and practice of pharmacy, 20th edition, Lippincott,Williams & Wilkins, page no: 930-943 3. New Drug Approval Process: second Edition, Revised and Expanded, edited by Richard A. Guarino page no: 39-64, 243-263 4.www.fda.gov/cder/handbook/indbox.htm 5.www.fda.gov/cder/handbook/ndabox.htm 6.www.fda.gov 03/22/15 46 List of references www.PharmInfopedia.com